Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Haematological malignancies

2495 - A Revised International Prognostic Score System for Waldenström’s Macroglobulinemia

Date

21 Oct 2018

Session

Proffered paper session - Haematological malignancies

Presenters

MARIA GAVRIATOPOULOU

Citation

Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286

Authors

M. GAVRIATOPOULOU1, E. Kastritis2, P. Morel3, A. Duhamel4, M.C. Kyrtsonis5, E. Durot4, A. Symeonidis6, K. Laribi7, E. Hatjiharisi8, L. Ysebaert9, A. Vassou10, N. Giannakoulas11, G. Merlini12, P. Repousis13, M. Varettoni14, E. Michalis15, B. Hivert16, M. Michalis17, V. Leblond14, M.A.C. Dimopoulos1

Author affiliations

  • 1 Oncology Department, Alexandra Hospital, 115 28 - Athens/GR
  • 2 Oncology Department, Alexandra Hospital, 11528 - ATHENS/GR
  • 3 Chu Amiens Picardie, Service D’hematologie Clinique Therapie Cellulaire, 80054 Amiens, France, Centre Hospitalier de Lens, 62300 - Lens/FR
  • 4 Univ. Lille, Chu Lille, Ea2694 – Santé Publique : épidémiologie Et Qualité Des Soins, F59000 Lille, France, Univ. Lille, CHU Lille, EA2694 – Santé publique : épidémiologie et qualité des soins, F59000 Lille, France, F59000 - LILLE/FR
  • 5 Hematology Deprtment, laikon hospital, 12345 - Athens/GR
  • 6 Hematology Deprtment, patras general hospital, 12368 - patras/GR
  • 7 Hematology Deprtment, HOSPITAL LE MANS, 1234 - Le Mans/FR
  • 8 Hematology Deprtment, IPPOKRATEION HOSPITAL, 34567 - THESSALONIKI/GR
  • 9 Hematology Deprtment, Institut Claudius Regaud - IUCT Oncopole, 31059 - Toulouse/FR
  • 10 Hematology Deprtment, general ioannina hospital, 152 32 - Chalandri/GR
  • 11 Hematology Deprtment, larissa general hospital, 12789 - larissa/GR
  • 12 Hematology Deprtment, PAVIA HOSPITAL, 123456 - PAVIA/IT
  • 13 Hematology Deprtment, METAKSA HOSPITAL, 34588 - Athens/GR
  • 14 French Innovative Leukemia Organization, French Innovative Leukemia Organization, 12345 - LILLE/FR
  • 15 Hematology Deprtment, genikon kratikon hospital, 3456 - Athens/GR
  • 16 French Innovative Leukemia Organization, French Innovative Leukemia Organization, 34567 - LILLE/FR
  • 17 Hematology Deprtment, leukosia general hospital, 12345 - leukosia/CY
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2495

Background

Waldenström’s Macroglobulinemia (WM) is an indolent disease with variable clinical presentation and heterogeneous prognosis. A robust and validated staging system was developed a decade ago, however, since then the treatment of the disease has changed. A revised staging system may better capture the prognosis of WM patients in the chemoimmunotherapy era.

Methods

We initially developed the revised system based on data from 492 patients included in the database of the Greek Myeloma Study Group with at least 3 years and a median of 7 years of follow up. An independent validation cohort included 229 symptomatic patients treated in institutions in France and Italy.

Results

we identified that age (≤65 years vs 66-75 vs ≥ 76 years), b2-microglobulin ≥4 mg/L, serum albumin <3.5 gr/dl and LDH ≥250 IU/L can be used to stratify patients in 5 different prognostic groups and identify a very low risk group as well as a very high-risk group. The revised ISSWM identified groups with different outcomes interdependent of age, type of primary therapy or reason to initiate therapy. This simple staging system was further validated in an independent cohort.

Conclusions

A revised IPSSWM may improve patient risk stratification, is easily available and may be used in the everyday practice to provide prognostic information.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Editorial Acknowledgement

NONE

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.